Drug class in one race
NMDA receptor drugs for Parkinson's Disease
2 tracked NMDA receptor drugs in the Parkinson's Disease race. The class explanation lives on the NMDA receptor page; the full indication pipeline across every mechanism is on the Parkinson's Disease page.
1 approved / phase 41 Phase 2
Head-to-head evidence: Amantadine ER (Gocovri/ADS-5102) vs AV-101